Walvax Biotechnology Co., Ltd. (SHE:300142)
China
· Delayed Price · Currency is CNY 11.79
+0.11 (0.94%)
Mar 9, 2026, 3:04 PM CST
Walvax Biotechnology Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 6, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Market Capitalization | 18,856 | 19,320 | 37,601 | 64,274 | 89,423 | 59,516 | Upgrade
|
| Market Cap Growth | -3.76% | -48.62% | -41.50% | -28.12% | 50.25% | 19.33% | Upgrade
|
| Enterprise Value | 18,707 | 18,563 | 36,117 | 62,959 | 88,584 | 58,587 | Upgrade
|
| Last Close Price | 11.79 | 12.04 | 23.41 | 40.00 | 55.91 | 38.33 | Upgrade
|
| PE Ratio | 382.91 | 135.90 | 89.66 | 88.21 | 209.06 | 59.33 | Upgrade
|
| Forward PE | 72.55 | 37.75 | 42.75 | 54.68 | 56.13 | 42.78 | Upgrade
|
| PS Ratio | 7.86 | 6.85 | 9.14 | 12.64 | 25.82 | 20.25 | Upgrade
|
| PB Ratio | 1.72 | 1.68 | 3.30 | 5.85 | 8.94 | 7.58 | Upgrade
|
| P/TBV Ratio | 2.14 | 2.31 | 4.57 | 8.15 | 11.16 | 9.54 | Upgrade
|
| P/FCF Ratio | 198.85 | 39.71 | 199.74 | 582.65 | - | - | Upgrade
|
| P/OCF Ratio | 33.86 | 18.64 | 33.16 | 53.50 | 126.79 | 521.18 | Upgrade
|
| EV/Sales Ratio | 7.80 | 6.58 | 8.78 | 12.38 | 25.58 | 19.93 | Upgrade
|
| EV/EBITDA Ratio | 148.74 | 47.89 | 32.22 | 44.27 | 95.49 | 51.04 | Upgrade
|
| EV/EBIT Ratio | - | 773.04 | 43.46 | 53.63 | 111.82 | 57.22 | Upgrade
|
| EV/FCF Ratio | 197.27 | 38.16 | 191.86 | 570.72 | - | - | Upgrade
|
| Debt / Equity Ratio | 0.03 | 0.04 | 0.07 | 0.04 | 0.03 | 0.01 | Upgrade
|
| Debt / EBITDA Ratio | 2.16 | 1.19 | 0.70 | 0.32 | 0.34 | 0.03 | Upgrade
|
| Debt / FCF Ratio | 2.87 | 1.01 | 4.28 | 4.19 | - | - | Upgrade
|
| Net Debt / Equity Ratio | -0.13 | -0.28 | -0.31 | -0.31 | -0.31 | -0.24 | Upgrade
|
| Net Debt / EBITDA Ratio | -13.98 | -8.44 | -3.17 | -2.40 | -3.37 | -1.67 | Upgrade
|
| Net Debt / FCF Ratio | -14.86 | -6.72 | -18.90 | -30.92 | 7.85 | 6.56 | Upgrade
|
| Asset Turnover | 0.17 | 0.19 | 0.27 | 0.35 | 0.30 | 0.35 | Upgrade
|
| Inventory Turnover | 1.08 | 0.83 | 0.74 | 0.72 | 0.60 | 1.02 | Upgrade
|
| Quick Ratio | 2.60 | 2.63 | 2.37 | 2.24 | 2.07 | 3.00 | Upgrade
|
| Current Ratio | 3.52 | 2.98 | 2.73 | 2.55 | 2.37 | 3.36 | Upgrade
|
| Return on Equity (ROE) | -0.64% | 1.52% | 4.57% | 8.94% | 6.74% | 17.93% | Upgrade
|
| Return on Assets (ROA) | -1.41% | 0.10% | 3.36% | 5.06% | 4.25% | 7.68% | Upgrade
|
| Return on Invested Capital (ROIC) | -3.55% | 0.28% | 9.20% | 14.24% | 10.50% | 19.52% | Upgrade
|
| Return on Capital Employed (ROCE) | -2.70% | 0.20% | 6.70% | 9.90% | 7.60% | 12.50% | Upgrade
|
| Earnings Yield | 0.26% | 0.74% | 1.11% | 1.13% | 0.48% | 1.69% | Upgrade
|
| FCF Yield | 0.50% | 2.52% | 0.50% | 0.17% | -0.45% | -0.49% | Upgrade
|
| Dividend Yield | 0.26% | 0.08% | 0.04% | 0.03% | 0.05% | 0.18% | Upgrade
|
| Payout Ratio | 84.55% | 28.80% | 4.76% | 6.88% | 19.48% | 3.16% | Upgrade
|
| Buyback Yield / Dilution | 0.01% | 0.06% | 0.21% | -1.93% | -0.90% | -1.37% | Upgrade
|
| Total Shareholder Return | 0.27% | 0.15% | 0.26% | -1.91% | -0.85% | -1.18% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.